Avicanna AI Stock Analysis
Want to see TSE:AVCN full AI Analyst Report?
Avicanna (AVCN) AI Stock Analysis
Avicanna
(TSX:AVCN)
The score is primarily held down by weak profitability, persistent negative cash flow, and poor technical momentum. Positive adjusted EBITDA, improving margins year over year, low leverage, and product and international initiatives provide some offset, but the negative P/E and ongoing funding needs keep the overall rating near the bottom of the range.
Avicanna (AVCN) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 8.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 180.58K
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- 1.43
- Revenue Growth
- -3.32%
- EPS Growth
- -34.15%
- Country
- Canada
- Employees
- 112
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Avicanna Business Overview & Revenue Model
Company Description
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...
Avicanna Earnings Call Summary
The call was broadly positive. Management highlighted the first positive adjusted EBITDA quarter, improving operating results, stronger gross margins year-over-year, reduced expenses, improved working capital, growth in proprietary and international revenue, the launch and expansion of the QUIX portfolio, and progress in clinical, pharmaceutical, and international initiatives. These positives were tempered by a 10% year-over-year revenue decline, lower gross profit, sequential gross-margin compression, negative operating cash flow, the impact of Veterans Affairs Canada reimbursement changes, licensing revenue variability, debt obligations, and the company's low market valuation.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For Q4, management expects to continue the cost discipline, launch further QUIX SKUs across the Canadian market, improve the MyMedi percentage of sales, and generate “some early signals of international revenue growth”; it expects the majority of recent G&A savings to be recurring into Q4 and going into next year, expects to file an SR&ED claim every year going forward, and expects the Avicanna share of MyMedi sales to trend towards “40% to even 50% of the sales.” Management expects further SKU launches, margin efficiencies, and signals of growth going into Q4, early signals from SMGH this year and next year, significant pharmaceutical milestones going into 2027, and U.S. rescheduling “towards the end of this year or early next year.”
Avicanna Financial Statement Overview
Summary
Financial performance is very weak: revenue declined, the company remains unprofitable, and operating and free cash flow are negative. Low leverage and improved equity provide some support, but the underlying financial score is constrained by persistent losses and cash consumption.
Income Statement
25NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.65M | 25.48M | 25.46M | 16.79M | 4.05M | 3.27M |
| Gross Profit | 13.09M | 12.84M | 12.90M | 6.66M | 1.11M | 2.83M |
| EBITDA | -1.57M | -1.97M | -2.43M | -7.36M | -12.18M | -15.13M |
| Net Income | -2.69M | -2.84M | -3.62M | -8.74M | -14.73M | -16.77M |
Balance Sheet | ||||||
| Total Assets | 23.36M | 21.24M | 20.12M | 21.97M | 17.62M | 22.30M |
| Cash, Cash Equivalents and Short-Term Investments | 151.23K | 280.63K | 448.03K | 477.20K | 1.19M | 31.00K |
| Total Debt | 258.57K | 0 | 109.23K | 1.80M | 3.21M | 1.66M |
| Total Liabilities | 8.73M | 9.86M | 10.38M | 14.00M | 14.16M | 15.39M |
| Stockholders Equity | 5.16M | 2.84M | 2.31M | -112.50K | -383.56K | 1.15M |
Cash Flow | ||||||
| Free Cash Flow | -3.22M | -1.44M | -2.95M | -1.96M | -7.50M | -12.45M |
| Operating Cash Flow | -3.05M | -1.18M | -2.55M | -1.40M | -7.44M | -11.66M |
| Investing Cash Flow | -178.83K | -255.84K | -402.57K | -3.05M | 810.24K | 760.83K |
| Financing Cash Flow | 2.82M | 963.17K | 3.41M | 3.55M | 9.90M | 10.06M |
Avicanna Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCN, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCN.
Avicanna Peers Comparison
Overall Rating
TSE:LABS57Neutral
TSE:INNO45Neutral
TSE:AVCN42Neutral
TSE:CWEB42Neutral
TSE:PCLO39Underperform
TSE:CRDL38.3Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | CAD 27.77M | -9.23 | -7.66% | ― | -9.31% | 66.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | CAD 7.42M | -5.56 | -19.37% | ― | -19.20% | 42.54% | |
| 42Neutral | CAD 12.09M | -4.09 | -65.40% | ― | -3.32% | -34.15% | |
| 42Neutral | CAD 65.11M | -0.87 | -139.31% | ― | -9.90% | -35.35% | |
| 39Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% | |
| 38Underperform | CAD 167.72M | -4.19 | -159.80% | ― | ― | 19.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AVCN | Avicanna Inc | 0.09 | -0.17 | -65.38% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.25 | 0.12 | 87.97% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | 0.00 | 0.00% | |
| TSE:PCLO | Pharmacielo | 0.04 | 0.00 | 0.00% | |
| TSE:CRDL | Cardiol Therapeutics Inc. | 1.39 | -0.02 | -1.42% | |
| TSE:INNO | Innocan Pharma Corporation | 1.65 | -13.74 | -89.28% |
Avicanna Corporate Events
Avicanna Moves U.S. Listing to OTCQB to Bolster Investor Access
PositiveAvicanna Inc., a cannabinoid-focused biopharmaceutical company listed in Canada and Europe, is expanding its presence in the U.S. capital markets through a transition of its U.S. listing to the OTCQB tier effective October 16, 2026. The move to OTCQB...
Avicanna Expands MyMedi.ca Platform with Integrated Medical Cannabis Program in Canadian Healthcare
PositiveAvicanna has launched the MyMedi.ca Integrated Healthcare Program in Canada to embed healthcare provider-guided medical cannabis care within hospitals, specialty clinics, insurers and multidisciplinary healthcare networks. The initiative extends the...
Avicanna Secures Strategic Private Placement Led by Pharma Investor Michael Porter
PositiveAvicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products for global medical and pharmaceutical markets, has built a diversified platform spanning branded medical cannabis, a patient-centric care portal, clinical-...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
